Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen R Karpen

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 11, 2025
The Urgent Need for Breakthrough Therapies and a World Without Type 1 DiabetesLynn Starr, Sanjoy Dutta, Thomas Danne, et al.
Clinical Pharmacology and Therapeutics|June 16, 2023
T1dCteGui: A User-Friendly Clinical Trial Enrichment Tool to Optimize T1D Prevention Studies by Leveraging AI/ML Based Synthetic Patient PopulationMike Pauley, Nick Henscheid, Sarah E David, et al.
Diabetologia|July 22, 2022
Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studiesStephen R Karpen, Jessica L Dunne, Brigitte I Frohnert, et al.
Respiratory Research|September 6, 2015
Impaired cardiac and peripheral hemodynamic responses to inhaled β₂-agonist in cystic fibrosisErik H Van Iterson, Stephen R Karpen, Sarah E Baker, et al.
Clinical Toxicology (Philadelphia, Pa.)|September 6, 2017
Centruroides sculpturatus envenomation in three adult patients requiring treatment with antivenomNicholas B Hurst, Demis N Lipe, Stephen R Karpen, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 4, 2025
Perceptions of the Benefits and Risks of Novel Therapies for Type 1 Diabetes: A Qualitative StudyStephen R Karpen, Richard Mellor, Linda A DiMeglio, et al.
Respiratory Medicine|March 10, 2015
Effects of exercise intensity compared to albuterol in individuals with cystic fibrosisCourtney M Wheatley, Sarah E Baker, Mary A Morgan, et al.
Therapeutic Innovation & Regulatory Science|January 5, 2021
Effective Data Sharing as a Conduit for Advancing Medical Product DevelopmentStephen R Karpen, J Kael White, Ariana P Mullin, et al.
Clinical Pharmacology and Therapeutics|March 11, 2022
Leveraging Real-World Data for EMA Qualification of a Model-Based Biomarker Tool to Optimize Type-1 Diabetes Prevention StudiesJagdeep T Podichetty, Patrick Lang, Inish M O'Doherty, et al.
Respiratory Medicine|June 17, 2015
Moderate intensity exercise mediates comparable increases in exhaled chloride as albuterol in individuals with cystic fibrosisCourtney M Wheatley, Sarah E Baker, Mary A Morgan, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 11, 2025
The Urgent Need for Breakthrough Therapies and a World Without Type 1 DiabetesLynn Starr, Sanjoy Dutta, Thomas Danne, et al.
Clinical Pharmacology and Therapeutics|June 16, 2023
T1dCteGui: A User-Friendly Clinical Trial Enrichment Tool to Optimize T1D Prevention Studies by Leveraging AI/ML Based Synthetic Patient PopulationMike Pauley, Nick Henscheid, Sarah E David, et al.
Diabetologia|July 22, 2022
Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studiesStephen R Karpen, Jessica L Dunne, Brigitte I Frohnert, et al.
Respiratory Research|September 6, 2015
Impaired cardiac and peripheral hemodynamic responses to inhaled β₂-agonist in cystic fibrosisErik H Van Iterson, Stephen R Karpen, Sarah E Baker, et al.
Clinical Toxicology (Philadelphia, Pa.)|September 6, 2017
Centruroides sculpturatus envenomation in three adult patients requiring treatment with antivenomNicholas B Hurst, Demis N Lipe, Stephen R Karpen, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 4, 2025
Perceptions of the Benefits and Risks of Novel Therapies for Type 1 Diabetes: A Qualitative StudyStephen R Karpen, Richard Mellor, Linda A DiMeglio, et al.
Respiratory Medicine|March 10, 2015
Effects of exercise intensity compared to albuterol in individuals with cystic fibrosisCourtney M Wheatley, Sarah E Baker, Mary A Morgan, et al.
Therapeutic Innovation & Regulatory Science|January 5, 2021
Effective Data Sharing as a Conduit for Advancing Medical Product DevelopmentStephen R Karpen, J Kael White, Ariana P Mullin, et al.
Clinical Pharmacology and Therapeutics|March 11, 2022
Leveraging Real-World Data for EMA Qualification of a Model-Based Biomarker Tool to Optimize Type-1 Diabetes Prevention StudiesJagdeep T Podichetty, Patrick Lang, Inish M O'Doherty, et al.
Respiratory Medicine|June 17, 2015
Moderate intensity exercise mediates comparable increases in exhaled chloride as albuterol in individuals with cystic fibrosisCourtney M Wheatley, Sarah E Baker, Mary A Morgan, et al.
Pageof 2